Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 2:03 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 2,406 matching trials from the live ClinicalTrials.gov search.
Conditions
Infections, Human Immunodeficiency Virus and Tuberculosis
Interventions
GSK1349572, Placebo, Iohexol Injection, Para-aminohippurate infusion
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Latent Tuberculosis, End Stage Renal Disease, Renal Transplant Candidate for Right Kidney, Renal Transplant Candidate for Left Kidney
Interventions
1 month Rifapentine, Isoniazid and Vitamin B6
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 90 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
New Brunswick, New Jersey
Conditions
Pneumococcal Vaccines
Interventions
0.5 mL of the low dose VAX-31, 0.5 mL of the mid dose VAX-31, 0.5 mL of the high dose VAX-31, 0.5 mL dose of PCV20, 0.5 mL of the High-PFS dose VAX-31
Biological
Lead sponsor
Vaxcyte, Inc.
Industry
Eligibility
42 Days to 89 Days
Enrollment
900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
45
States / cities
Jonesboro, Arkansas • Gardena, California • Los Angeles, California + 32 more
Conditions
HIV Infections, Emphysema, Chronic Obstructive Pulmonary Disease, Pneumocystis
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
2
States / cities
Los Angeles, California • San Francisco, California
Conditions
Gonorrhea
Interventions
Listerine Antiseptic Mouthwash Product, Biotene Mouthwash
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 45 Years · Male only
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Cystic Fibrosis
Interventions
AZLI 75 mg two times a day (BID)/ three times a day (TID)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
6 Years and older
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
56
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 53 more
Conditions
Typhoid Fever
Interventions
BB IND 6989
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 45 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Atypical Mycobacterium Infection
Interventions
Interleukin-12
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Enterocolitis, Pseudomembranous Colitis, Antibiotic-associated Colitis
Interventions
Lactobacillus GG
Drug
Lead sponsor
Michael E. DeBakey VA Medical Center
Federal
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Houston, Texas
Conditions
Clostridium Difficile Infection Recurrence
Interventions
Full Spectrum Microbiota, Placebo
Drug
Lead sponsor
Finch Research and Development LLC.
Industry
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
54
States / cities
Scottsdale, Arizona • Los Angeles, California • Murrieta, California + 48 more
Conditions
Shigella
Interventions
CVD 1208S, Challenge strain of wild-type Shigella flexneri 2a
Biological
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
2
States / cities
Baltimore, Maryland
Conditions
Meningococcal Disease, Pregnancy, Infections, Meningococcal
Interventions
Meningococcal quadrivalent CRM-197 conjugate vaccine
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
Female only
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
Wilmington, North Carolina
Conditions
Hidradenitis Suppurativa
Interventions
23.4% Hypertonic saline
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Colon Cancer, Lung Cancer, Tobacco Use Cessation, Obesity, Pneumonia, Bacterial, Shingles, Hepatitis C
Interventions
Epic Healthy Planet Population Health Module
Other
Lead sponsor
University of California, Davis
Other
Eligibility
50 Years to 80 Years
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Sacramento, California
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy of SUM-191 for Patients With Bacterial Conjunctivitis

NCT07565103
Conditions
Bacterial Conjunctivitis
Interventions
SUM-191, Placebo
Drug
Lead sponsor
Senju USA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
426 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
2
States / cities
Delray Beach, Florida • Austin, Texas
Conditions
Chlamydial Infection, Gonorrhoea, Trichomoniasis
Interventions
Click Device
Device
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
14 Years to 99 Years · Female only
Enrollment
295 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
8
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 5 more
Completed Phase 4 Interventional Accepts healthy volunteers

Study to Eliminate Hib Carriage in Rural Alaska Native Villages

NCT00153556
Conditions
Haemophilus Influenzae Type B, Carrier State
Interventions
Hib conjugate vaccine (HbOC, Wyeth Vaccines)
Biological
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
0 Years and older
Enrollment
3,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2003
U.S. locations
1
States / cities
Anchorage, Alaska
Conditions
Gonorrhea
Interventions
Delafloxacin, Ceftriaxone
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
15 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
25
States / cities
Birmingham, Alabama • Chula Vista, California • La Mesa, California + 21 more
Conditions
Clostridioides Difficile Infection
Interventions
Health counseling sessions, Diet (control diet), Diet (experimental diet)
Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Group B Streptococcal Infections
Interventions
Group B streptoccous 6-valent polysaccharide conjugate vaccine (GBS6)
Biological
Lead sponsor
Pfizer
Industry
Eligibility
20 Years to 51 Years
Enrollment
151 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
4
States / cities
Stockbridge, Georgia • Bardstown, Kentucky • Salt Lake City, Utah
Conditions
Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Pentamidine isethionate, Dapsone
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1994
U.S. locations
14
States / cities
San Francisco, California • Denver, Colorado • Wilmington, Delaware + 10 more
Completed Phase 4 Interventional Accepts healthy volunteers

Pediatric Subjects With Tinea Corporis

NCT02227290
Conditions
Tinea Corporis
Interventions
Naftin Cream, Placebo Cream
Drug
Lead sponsor
Merz North America, Inc.
Industry
Eligibility
2 Years to 17 Years
Enrollment
230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
14
States / cities
Tucson, Arizona • Encino, California • Fremont, California + 10 more
Conditions
Hidradenitis Suppurativa (HS)
Interventions
Soquelitinib
Drug
Lead sponsor
Corvus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
11
States / cities
West Lafayette, Indiana • Bowling Green, Kentucky • Owensboro, Kentucky + 8 more
Conditions
Pneumococcal Infections
Interventions
Multivalent, Tdap
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 49 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut